State Street’s Lakewood-Amedex Biotherapeutics LABT Stock Holding History
Bought
Maintained
Sold
Other funds holding LABT
State Street's LABT Position: Q3 2026 in Review
State Street opened a new position in Lakewood-Amedex Biotherapeutics (LABT) in Q3 2026: 24,000 shares worth $22.9K. The stake represents ﹤0.01% of the portfolio and ranks #4243 among its holdings.
7 funds tracked by Wall St. Rank hold LABT as of Q3 2026.
- State Street held 24,000 shares of Lakewood-Amedex Biotherapeutics worth $22.9K as of Q3 2026.
- Lakewood-Amedex Biotherapeutics was a new State Street position in Q3 2026.
- Lakewood-Amedex Biotherapeutics made up ﹤0.01% of State Street's portfolio in Q3 2026, its #4243 holding.
- 7 funds tracked by Wall St. Rank held Lakewood-Amedex Biotherapeutics as of Q3 2026.
Based on State Street's 13F filing for Q3 2026, filed 12 Nov 2026.